The Relationship Between Serum Uric Acid and Ejection Fraction of the Left Ventricle

Overview

Journal J Clin Med

Specialty General Medicine

Date 2021 Sep 10

PMID 34501474

Citations 3

Authors

Ivan Vlad-Sabin

Buzas Roxana

Cutina Morgovan Adina-Flavia

Ciubotaru Paul

Ardelean Melania

Goje Daniel

Rosca Ciprian Ilie

Timar Romulus

Lighezan Daniel

Affiliations

Soon will be listed here.

Abstract

As a byproduct of protein metabolism, serum uric acid is a controversial risk factor and is the focus of several recent studies in the field of cardiovascular disease. Whether serum uric acid is involved in the development of these pathologies alone or in conjunction with other factors is a matter of debate. The objective of this study is to assess the direct relationship between serum uric acid and the ejection fraction. A retrospective study of 303 patients with heart failure, classified according to the ESC guidelines, was conducted, and several parameters, along with the relationship between serum uric acid and ejection fraction, were characterized. A direct relationship between the level of serum uric acid and the ejection fraction was established ( 0.03); patients with higher uric acid had an increased risk of having a lower ejection fraction. : Serum uric acid, even when asymptomatic, is linked with the level of the ejection fraction of the left ventricle.

Citing Articles

The Role of Hyperuricemia in Cardiac Diseases: Evidence, Controversies, and Therapeutic Strategies.

Zheng Y, Chen Z, Yang J, Zheng J, Shui X, Yan Y Biomolecules. 2024; 14(7).

PMID: 39062467 PMC: 11274514. DOI: 10.3390/biom14070753.

Total 25-Hydroxyvitamin D Is an Independent Marker of Left Ventricular Ejection Fraction in Heart Failure with Reduced and Mildly Reduced Ejection Fraction.

Szabo T, Nagy E, Kirchmaier A, Heidenhoffer E, Gabor-Kelemen H, Frasineanu M Biomolecules. 2023; 13(11).

PMID: 38002259 PMC: 10669750. DOI: 10.3390/biom13111578.

The effect of serum uric acid concentration on the severity of chronic congestive heart failure.

Alshamari A, Kadhim R, Al-Mohana S J Med Life. 2023; 15(12):1569-1572.

PMID: 36762335 PMC: 9884355. DOI: 10.25122/jml-2022-0068.

References

Zhang T, Pope J . Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis. Rheumatology (Oxford). 2017; 56(7):1144-1153. DOI: 10.1093/rheumatology/kex065. View

Huang H, Huang B, Li Y, Huang Y, Li J, Yao H . Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail. 2013; 16(1):15-24. DOI: 10.1093/eurjhf/hft132. View

Spinar J, Spinarova L, Malek F, Ludka O, Krejci J, Ostadal P . Prognostic value of NT-proBNP added to clinical parameters to predict two-year prognosis of chronic heart failure patients with mid-range and reduced ejection fraction - A report from FAR NHL prospective registry. PLoS One. 2019; 14(3):e0214363. PMC: 6435170. DOI: 10.1371/journal.pone.0214363. View

Sarhene M, Wang Y, Wei J, Huang Y, Li M, Li L . Biomarkers in heart failure: the past, current and future. Heart Fail Rev. 2019; 24(6):867-903. DOI: 10.1007/s10741-019-09807-z. View

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M . 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39(33):3021-3104. DOI: 10.1093/eurheartj/ehy339. View

Vasan R, Xanthakis V, Lyass A, Andersson C, Tsao C, Cheng S . Epidemiology of Left Ventricular Systolic Dysfunction and Heart Failure in the Framingham Study: An Echocardiographic Study Over 3 Decades. JACC Cardiovasc Imaging. 2017; 11(1):1-11. PMC: 5756128. DOI: 10.1016/j.jcmg.2017.08.007. View

Savarese G, Xu H, Trevisan M, Dahlstrom U, Rossignol P, Pitt B . Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. JACC Heart Fail. 2018; 7(1):65-76. DOI: 10.1016/j.jchf.2018.10.003. View

Kanbay M, Afsar B, Siriopol D, Dincer N, Erden N, Yilmaz O . Effect of Uric Acid-Lowering Agents on Cardiovascular Outcome in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Clinical Studies. Angiology. 2020; 71(4):315-323. DOI: 10.1177/0003319719897509. View

Caraballo C, Desai N, Mulder H, Alhanti B, Wilson F, Fiuzat M . Clinical Implications of the New York Heart Association Classification. J Am Heart Assoc. 2019; 8(23):e014240. PMC: 6912957. DOI: 10.1161/JAHA.119.014240. View

10.

Borghi C, Agabiti Rosei E, Bardin T, Dawson J, Dominiczak A, Kielstein J . Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 2015; 33(9):1729-41. DOI: 10.1097/HJH.0000000000000701. View

11.

Asano R, Kajimoto K, Oka T, Sugiura R, Okada H, Kamishima K . Association of New York Heart Association functional class IV symptoms at admission and clinical features with outcomes in patients hospitalized for acute heart failure syndromes. Int J Cardiol. 2017; 230:585-591. DOI: 10.1016/j.ijcard.2016.12.052. View

12.

Piepoli M, Hoes A, Agewall S, Albus C, Brotons C, Catapano A . 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by.... Eur Heart J. 2016; 37(29):2315-2381. PMC: 4986030. DOI: 10.1093/eurheartj/ehw106. View

13.

Pitt B, Rossignol P . The safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure. Expert Opin Drug Saf. 2016; 15(5):659-65. DOI: 10.1517/14740338.2016.1163335. View

14.

Nanayakkara S, Haykowsky M, Mariani J, van Empel V, Maeder M, Vizi D . Hemodynamic Profile of Patients With Heart Failure and Preserved Ejection Fraction Vary by Age. J Am Heart Assoc. 2017; 6(9). PMC: 5634249. DOI: 10.1161/JAHA.116.005434. View

15.

Lim F, Yap J, Gao F, Teo L, Lam C, Yeo K . Correlation of the New York Heart Association classification and the cardiopulmonary exercise test: A systematic review. Int J Cardiol. 2018; 263:88-93. DOI: 10.1016/j.ijcard.2018.04.021. View

16.

Malek F, Ostadal P, Parenica J, Jarkovsky J, Vitovec J, Widimsky P . Uric acid, allopurinol therapy, and mortality in patients with acute heart failure--results of the Acute HEart FAilure Database registry. J Crit Care. 2012; 27(6):737.e11-24. DOI: 10.1016/j.jcrc.2012.03.011. View

17.

Hao G, Wang X, Chen Z, Zhang L, Zhang Y, Wei B . Prevalence of heart failure and left ventricular dysfunction in China: the China Hypertension Survey, 2012-2015. Eur J Heart Fail. 2019; 21(11):1329-1337. DOI: 10.1002/ejhf.1629. View

18.

Doehner W, Jankowska E, Springer J, Lainscak M, Anker S . Uric acid and xanthine oxidase in heart failure - Emerging data and therapeutic implications. Int J Cardiol. 2015; 213:15-9. DOI: 10.1016/j.ijcard.2015.08.089. View

19.

Spoletini I, Coats A, Senni M, Rosano G . Monitoring of biomarkers in heart failure. Eur Heart J Suppl. 2020; 21(Suppl M):M5-M8. PMC: 6937510. DOI: 10.1093/eurheartj/suz215. View

20.

Carnicelli A, Sun J, Alhanti B, Bjursell M, Perl S, Lytle B . Elevated Uric Acid Prevalence and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from RELAX. Am J Med. 2020; 133(12):e716-e721. DOI: 10.1016/j.amjmed.2020.03.054. View